Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Di Maio
Massimo
M
Clinical Trials Unit, National Cancer Institute-G.Pascale Foundation, Napoli, Italy. dimaiomax@libero.it
Daniele
Bruno
B
Perrone
Francesco
F
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D005355:Fibrosis / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology* / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017410:Practice Guidelines as Topic; D011725:Pyridines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000077157:Sorafenib; D016019:Survival Analysis; D013997:Time Factors
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
N Engl J Med. 2008 Jul 24;359(4):378-90
18650514
Lancet Oncol. 2009 Jan;10(1):25-34
19095497
J Clin Oncol. 2009 Apr 10;27(11):1800-5
19255312
Oncologist. 2009 Jan;14(1):95-100
19144678
Br J Surg. 1973 Aug;60(8):646-9
4541913
Oncologist. 2009 Jan;14(1):70-6
19144684
J Clin Gastroenterol. 2009 May-Jun;43(5):489-95
19247201
J Natl Cancer Inst. 2008 May 21;100(10):698-711
18477802
Oncologist. 2009 Jan;14(1):67-9
19147690